Varenicline for Nicotine Dependence Among Those With HIV/AIDS
A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS
Sponsor: National Institute on Drug Abuse (NIDA)
Listed as NCT01710137, this PHASE3 trial focuses on Nicotine Dependence and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 12 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2018 — Oct 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2018 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Drug Abuse (NIDA)
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .